Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy-Reference-Cited by-同舟云学术

Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy

Published:2016-12 Issue:12 Volume:27 Page:2288-2294
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Ahmed K.A.,Abuodeh Y.A.,Echevarria M.I.,Arrington J.A.,Stallworth D.G.,Hogue C.,Naghavi A.O.,Kim S.,Kim Y.,Patel B.G.,Sarangkasiri S.,Johnstone P.A.S.,Sahebjam S.,Khushalani N.I.,Forsyth P.A.,Harrison L.B.,Yu M.,Etame A.B.,Caudell J.J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/12/2288/13789487/mdw417.pdf

Reference24 articles.

1. Prognostic factors for survival in melanoma patients with brain metastases;Davies;Cancer,2011

2. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients;Sperduto;Int J Radiat Oncol Biol Phys,2010

3. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol,2015

4. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial;Long;Lancet,2015

5. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial;Long;Lancet Oncol,2012

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of melanoma brain metastases with radiation and immunotherapy or targeted therapy: A systematic review with meta-analysis;Critical Reviews in Oncology/Hematology;2024-10

2. Factors associated with the local control of brain metastases: a systematic search and machine learning application;BMC Medical Informatics and Decision Making;2024-06-21

3. Immune Response to Molecular Radiotherapy with ¹⁷⁷Lu-DOTATOC: Predictive Value of Blood Cell Counts for Therapy Outcome;Cancer Biotherapy and Radiopharmaceuticals;2024-06-21

4. Local and Systemic Management Options for Melanoma Brain Metastases;The Cancer Journal;2024-03

5. Which is the best treatment for melanoma brain metastases? A Bayesian network meta-analysis and systematic review;Critical Reviews in Oncology/Hematology;2024-02